Urinary stress incontinence - female
Also known as: Urine, Urinary, Urinate
Methodology & AI Transparency ⓘ
Urinary stress incontinence - female Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Urinary stress incontinence - female (also termed Urine or Urinary) (ICD-10-CM N39.3), Prostate (BPH), Bladder & Urinary Tract protocols prioritize urinalysis/urine culture [Urinary stress incontinence - female N39.3] paired with baseline and interval Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) assessment.
- 2 Real-world patient consensus: Synonyms for Urinary stress incontinence - female (N39.3): Urine, Urinary, Urinate (Urology & Prostate).
- 3 Typical cash cost range: Primary evaluation for Urinary stress incontinence - female incorporates urinalysis/urine culture [Urinary stress incontinence - female N39.3] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Urinary stress incontinence - female: maintaining Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) within Age-specific PSA; eGFR > 75 mL/min (N39.3).
Ask our AI Specialists anything about Urinary stress incontinence - female
What Is Urinary stress incontinence - female?
For patients presenting with Urinary stress incontinence - female (also termed Urine or Urinary) (ICD-10-CM N39.3), Prostate (BPH), Bladder & Urinary Tract protocols prioritize urinalysis/urine culture [Urinary stress incontinence - female N39.3] paired with baseline and interval Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Urinary stress incontinence - female (code N39.3) is alpha-1A adrenergic smooth-muscle in Urinary stress incontinence - female (N39.3: tone narrowing the), which Prostate (BPH), Bladder & Urinary Tract clinicians address while surveilling Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) (Age-specific PSA; eGFR > 75 mL/min (N39.3)).
Common Symptoms & Clinical Signs
- • Presentation of Urinary stress incontinence - female (N39.3): weak, hesitant, or in Urinary stress incontinence - female (N39.3: intermittent urinary stream)
- • Secondary Urinary stress incontinence - female clinical sign: waking two or in Urinary stress incontinence - female (N39.3: more times nightly)
- • Symptom flares in Urinary stress incontinence - female correlating with Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) deviation outside Age-specific PSA; eGFR > 75 mL/min (N39.3)
- • Functional urology & prostate impact requiring urinalysis/urine culture [Urinary stress incontinence - female N39.3] evaluation (N39.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Urinary stress incontinence - female Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N39.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Total PSA & in Urinary stress incontinence - female (N39.3: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N39.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Urinary stress incontinence - female (N39.3: Score) | 0 – 7 (mild symptoms) (N39.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Urinary stress incontinence - female (N39.3: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N39.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Urinary stress incontinence - female
Treatment selection for Urinary stress incontinence - female depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Urinary stress incontinence - female)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Replacement Therapy on Lower Urinary Tract: What a 2,029-Participant Study Found In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. European urology • 2016-06-15 • Meta-Analysis | N = 2,029 | 99/100 | PMID 26874809 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of testosterone replacement therapy on lower urinary tract: What a 2,453-Participant Study Found The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Journal of evidence-based medicine • 2024-09-15 • Meta-Analysis | N = 2,453 | 99/100 | PMID 39004879 ↗ |
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated: What a 2,222-Participant Study Found Sulopenem was noninferior to amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection, but was associated with more frequent mild side effects. NEJM evidence • 2025-07-15 • Phase III Randomized Trial | N = 2,222 | 96/100 | PMID 40552968 ↗ |
Urinary stress incontinence - female Patient Community & “People Like Me” Threads
Filter Urinary stress incontinence - female community threads and patient logs by age, biological sex, dosage, and treatment duration.